KELSEY STAPLETON: Open Payments
NPI 1609364785 · ABINGDON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,229 in 141 payments from 24 companies in 2025. Trend: 2023 $1,999 · 2024 $2,066 · 2025 $2,229
Food & beverage: $2,229
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $465 |
| Novo Nordisk Inc | 16 | $251 |
| AstraZeneca Pharmaceuticals LP | 9 | $222 |
| Amgen Inc. | 25 | $206 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $194 |
| Astellas Pharma US Inc | 4 | $96 |
| Axsome Therapeutics, Inc. | 5 | $91 |
| Novartis Pharmaceuticals Corporation | 4 | $83 |
| PFIZER INC. | 5 | $74 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $73 |
Products named: CAPLYTA, UBRELVY, OTEZLA, AIRSUPRA, QULIPTA, Rybelsus, VRAYLAR, Veozah.
Industry payments across VA — which companies pay providers there.
